According to Assertio Therapeutics 's latest financial reports the company's current revenue (TTM) is $0.15 B. In 2022 the company made a revenue of $0.15 B an increase over the years 2021 revenue that were of $0.11 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.15 B | -2.66% |
2022 | $0.15 B | 40.73% |
2021 | $0.11 B | 4.46% |
2020 | $0.10 B | -53.69% |
2019 | $0.22 B | -26.39% |
2018 | $0.31 B | -18.11% |
2017 | $0.38 B | -16.49% |
2016 | $0.45 B | 33.02% |
2015 | $0.34 B | -12.2% |
2014 | $0.39 B | 190.87% |
2013 | $0.13 B | 47.78% |
2012 | $90.81 M | -31.7% |
2011 | $0.13 B | 64.64% |
2010 | $80.76 M | 39.91% |
2009 | $57.72 M | 65.69% |
2008 | $34.84 M | -46.87% |
2007 | $65.58 M | 586.64% |
2006 | $9.55 M | 116.81% |
2005 | $4.4 M | |
2003 | $0.98 M | -40.89% |
2002 | $1.66 M | -54.78% |
2001 | $3.67 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
OPKO Health
OPK | $0.86 B | 467.83% | ๐บ๐ธ USA |
Onconova Therapeutics ONTX | $0.22 M | -99.85% | ๐บ๐ธ USA |